biotech · Pulmonary Arterial Hypertension · Pulmonary Arterial Hypertension (PAH) · IKT
Inhibikase Therapeutics
Inhibikase Therapeutics patent portfolio — 9 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Wilmington, USA
- Employees
- 29
- Programs
- 4
- Drugs
- 5
- Patents
- 9
Inhibikase Therapeutics patents
9 pharmaceutical patents indexed for Inhibikase Therapeutics. 0 expire within 24 months.
Inhibikase Therapeutics has 9 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11725005
Compositions and methods for inhibiting kinases
granted -
US 11407747
Compositions and methods for inhibiting kinases
granted -
US 10906896
Compositions and methods for inhibiting kinases
granted -
US 10344027
Compositions and methods for inhibiting kinases
granted -
US 10316031
Compositions and methods for inhibiting kinases
granted -
US 10118923
Compositions and methods for inhibiting kinases
granted -
US 9907796
Methods of treating tumoral diseases, or bacterial or viral infections
granted -
US 9828370
Compositions and methods for inhibiting kinases
granted -
US 9487500
Compounds and compositions thereof
granted
Frequently asked questions
How many patents does Inhibikase Therapeutics have?
9 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Inhibikase Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.